GastroPanel

GastroPanel is a laboratory blood test that measures selected biomarkers associated with the structure and function of the gastric mucosa. This specific panel includes gastrin-17, pepsinogen I, and pepsinogen II. The relationship between these values can provide complementary information about gastric acid regulation, the functional state of different parts of the stomach, and patterns that may require further medical evaluation.

The test may be considered when upper digestive symptoms are persistent or recurrent, including heartburn and upper abdominal discomfort, abdominal pain and cramps after eating, or bloating after meals. These symptoms can have many different causes, and the biomarker results cannot determine the cause without considering the person’s medical history, medications, previous findings, and current symptoms.

What GastroPanel measures

Gastrin-17 and pepsinogens are produced in different areas of the stomach and are involved in gastric acid regulation and protein digestion. Assessing them together can help describe certain functional and mucosal patterns more clearly than an isolated measurement.

• Gastrin-17: a hormone produced mainly in the antral part of the stomach. It participates in regulating gastric acid secretion, gastric motility, pepsin release, and mucosal growth.
• Pepsinogen I: produced predominantly in the body and fundus of the stomach. Its concentration can provide information related to the condition of the acid-producing gastric mucosa.
• Pepsinogen II: produced across a wider area of the stomach and the upper small intestine. It is interpreted together with pepsinogen I and the clinical context.
• PGI/PGII relationship: the relationship between pepsinogen I and II may support assessment of gastric corpus mucosa and patterns compatible with atrophic changes.

This specific panel does not include testing for Helicobacter pylori. A separate test may be required when current or previous H. pylori infection needs to be assessed.

When the test may be considered

GastroPanel may be useful as part of the evaluation of prolonged dyspeptic symptoms, especially when discomfort continues despite dietary changes or nonprescription treatment. It may also be considered in people with a history of chronic gastritis, gastric ulcer, gastric polyps, prolonged H. pylori infection, or a family history of malignant gastrointestinal disease.

Smoking, frequent alcohol consumption, unsuitable dietary habits, obesity, and metabolic syndrome may also influence the decision to assess gastric health. These factors do not by themselves indicate that a person has a specific stomach disorder, but they can be considered together with symptoms and medical history.

The test is not intended to determine whether symptoms are harmless or serious on its own. Persistent symptoms, progressive difficulty swallowing, unexplained weight loss, repeated vomiting, anemia, gastrointestinal bleeding, or severe abdominal pain require timely clinical assessment.

What the biomarker pattern may help assess

Gastrin-17 and gastric acid regulation

Gastrin-17 supports the regulation of gastric acid production. A lower or higher value may have different explanations. Values can be influenced by acid secretion, the functional condition of the antral mucosa, food intake, and medicines that reduce gastric acid. The result must therefore be interpreted as part of the complete biomarker pattern rather than as an isolated diagnosis.

Pepsinogen I, pepsinogen II, and gastric mucosa

Pepsinogen I and II are inactive precursors of pepsin, an enzyme involved in protein digestion. Their concentrations and relationship can provide information about the gastric corpus mucosa. A reduced pepsinogen I concentration or an altered PGI/PGII relationship may support suspicion of atrophic mucosal changes, but laboratory values alone cannot confirm the location, severity, or cause of those changes.

Pepsinogen II may also change with inflammation of the gastric mucosa. Because it is not specific to one condition, interpretation requires comparison with pepsinogen I, gastrin-17, symptoms, medication use, and previous medical findings.

How GastroPanel testing works

Step 1: Review of symptoms and medical information

Before testing, it is useful to record how long the symptoms have been present, whether they are related to meals, and whether there is a previous diagnosis of gastritis, ulcer disease, or H. pylori infection. Previous gastroscopy, biopsy, or laboratory reports can help with later interpretation.

Step 2: Confirming preparation instructions

The preparation instructions should be confirmed when the appointment is arranged, including whether fasting is required. Acid-suppressing medicines may affect gastrin and pepsinogen values. Prescription treatment should not be stopped or changed unless a doctor provides specific instructions.

Step 3: Blood sample collection

A venous blood sample is collected. The blood draw usually takes only a few minutes and does not require sedation, contrast material, or a recovery period.

Step 4: Laboratory analysis

The sample is analyzed for gastrin-17, pepsinogen I, and pepsinogen II. The relationship between the pepsinogen values is considered together with the individual results.

Step 5: Report and possible follow-up

The laboratory report is typically available within a few hours. The findings may support a decision about whether clinical monitoring, medication review, separate H. pylori testing, gastroenterology consultation, gastroscopy, or another examination should be considered.

Clinical limitations of GastroPanel

GastroPanel provides complementary laboratory information. It does not directly show the inside of the stomach, identify a visible lesion, or provide tissue for histological analysis. It therefore does not replace gastroscopy, biopsy, or a gastroenterology examination when these are clinically indicated.

A value outside the reference range does not establish a diagnosis by itself, while values within the reference range do not exclude every gastric disorder. Interpretation may be affected by acid-suppressing medication, previous stomach treatment, H. pylori status, kidney function, and other individual factors.

Practical next step

When sending an inquiry, include a short description of the symptoms, how long they have been present, their relationship to meals, current medication, and any previous gastroscopy, biopsy, H. pylori, or laboratory findings. This information can help clarify whether GastroPanel is an appropriate first laboratory step or whether a gastroenterology assessment or another examination should be considered first.

You can send an inquiry to arrange GastroPanel testing and receive practical information about preparation, sample collection, and the next step after the report.